Momenta Ventures Invests in IoT Connectivity Company Thingstream
29.10.2019 13:00:00 EET | Business Wire | Press release
Thingstream, a leading provider of IoT Connectivity-as-a-Service, announces an investment from Momenta Ventures, a Digital Industry venture investment firm.
With Thingstream successfully separating from its incubating company Myriad Group earlier this year, Momenta Ventures’ investment marks a significant milestone to scale growth. “We are happy to have Momenta Ventures on-board. Their deep industry knowledge about Digital Industry and their commitment to Low Power, Wide Area Networks (LPWAN) is unique. Momenta’s investment in Thingstream is a significant affirmation of our mission to connect the enterprise via LPWAN, unlocking the potential of IoT”, says Philipp Bolliger, CEO Thingstream.
Thingstream offers simple to use connectivity solutions, supporting asset tracking, remote monitoring and related Industrial IoT use cases. Its solutions support low-power, secure connectivity with coverage across more than 190 countries. Thingstream’s holistic approach to connectivity accelerates enterprise projects by removing common barriers to collecting data from IoT devices thus unlocking the promise of IoT for enterprise customers worldwide. Thingstream supports connectivity through license spectrum cellular technologies today and are in the process of adding unlicensed LPWAN technologies including LoRaWAN to their offering.
Momenta Ventures’ Managing Director Ken Forster states “We’re excited to be supporting Thingstream in their journey to connect industrial devices world-wide. As practitioners in Digital Industry, we see reliable, low-cost connectivity as a critical enabler for enterprise IoT solutions. We believe that ubiquitous LPWAN devices, networks and applications, across licensed and unlicensed spectrum, will drive dramatic growth in scope and volume in the next few years.” Mr. Forster continues, “We believe our investment in Thingstream will further accelerate this LPWAN trend in Digital Industry, thus complementing our other ecosystem investments”.
Thingstream is preparing for a Series A investment and will be exhibiting at the premier event for the Industrial IoT: IoT Solutions World Congress in Barcelona (29-31 October), where they plan to make several key industry announcements.
About Thingstream
Thingstream is a leading provider of Connectivity-as-a-Service for the Internet of Things (IoT) applications. Thingstream’s intelligent Global Connectivity Platform provides low power, low cost, ubiquitous IoT connectivity via MQTT and works in over 190 countries already today. The secure, out-of-the-box IoT connectivity solution leverages both the globally-available GSM network as well as private LoRaWAN implementation to offer immediate, global IoT connectivity that no other low power connectivity provider can today. Thingstream specialises in helping simplify IoT connectivity, reducing costs and operational overheads in the delivery of an intelligent network of connected things. For more information visit https://thingstream.io.
About Momenta Ventures
Momenta Ventures is the investment arm of Momenta Partners, the leading Digital Industry Growth Partner firm. Led by deep operating practitioners with strong entrepreneurial and corporate track-records, Momenta Ventures has made over 30 investments with notable exits to SAP, PTC and Husqvarna Group. Momenta Ventures runs two Digital Industry ecosystem funds, focused on seed and Series A investments in Digital Energy, Manufacturing, Smart Spaces and Supply Chain globally. The most recent fund focuses on Digital Industry innovation powered by LPWAN, specifically LoRa and LoRaWAN. For more information visit https://momenta.vc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005492/en/
Contact information
Press contact for Thingstream:
Dan Walsh
MUSTARD PR
dan@mustardpr.com
+44 (0) 7827 816 971
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom